OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 131 - 140 of 796 studies

Infection

A phase 1, first-in-human safety and immunogenicity study of a Lassa fever vaccine, ChAdOx1 LassaJ, in healthy volunteers aged 18 – 55 years in the UK. (ViTaL01)

This is a first-in-human phase 1 trial to assess the safety,tolerability,and immunogenicity of two doses of ChAdOx1 LassaJ in healthy volunteers aged 18-55 years. There will be an initial lead-in cohort (cohort 1) of 6 participants,followed by a participant-observer blinded cohort of 25 participants cohort (cohort 2). Participants in cohort 2 will be randomly assigned to subgroups,one of which will receive 2 doses of the ChAdOx1 LassaJ vaccine 12 weeks apart (20 participants) and the other group will receive ...

GO TO STUDY Go

Respiratory

HypErpolarised Xenon PuLmonary MRI in the Evaluation for EndobronChial Lung Volume ReductIon Therapy (EXPLICIT) (Explicit)

COPD is the third leading cause of deaths worldwide. Lung volume reduction (LVR) therapy improves symptoms and life expectancy in severe COPD. The damaged lungs in COPD become overinflated which may cause compression of the more efficient parts of the lung. One-way expiratory endobronchial valves have been developed to be placed in the airways leading to the overinflated lung by bronchoscopy, only allowing air to exit the lung causing deflation and LVR. In some cases, air can enter the targeted ...

GO TO STUDY Go

Cancer and neoplasms

Stratified Medicine Paediatrics 2

StratMedPaeds2 aims to develop new tests that identify treatment for children who fail therapy and experience cancer relapse. It builds on the success achieved in StratMedPaeds1, which provided a national pathway to molecularly test tumour tissue and blood in children who relapse, and feed usable information about treatment and mechanisms of treatment failure to clinicians and researchers seeking to improve survival for these children. Having delivered several effective tests to the NHS, StratMedPaeds2 will move on to address four important ...

GO TO STUDY Go

Skin

Study of Immune responses in inflammatory skin diseases

Inflammatory skin diseases account for an enormous physical and psychological burden. Although there have been tremendous improvements in the range of available treatments, there remains a major unmet medical need, not least of all because the majority of the advances are only approved for those with the most severe forms of disease. The other 80-90% of affected individuals are largely unable to benefit. Here, we aim to study the immune responses which are involved in driving skin ...

GO TO STUDY Go

Cancer and neoplasms

Getting Recovery Right After Neck Dissection for Head and Neck Cancer (GRRAND)

Head and neck cancer affects the mouth, throat, salivary glands, voice box, nose or sinuses. Every year over 12,000 people get head and neck cancer. It is the 8th most common form of cancer. Over recent years many more people, particularly young people, have developed head and neck cancers. Many of these cancers are removed surgically. Some people also need radiotherapy or chemotherapy. Treatments are improving and better at getting rid of these cancers. Neck dissection is a common operation ...

GO TO STUDY Go

Cancer and neoplasms

National Study of Adrenal Tumours

This is a study putting together large numbers of patients with or without a hereditary risk of adrenal tumours including tumours such as adrenocortical carcinoma and phaeochromocytoma/paraganglioma. The purpose is to answer questions about the survival of patients with these rare tumours and to do this, we will collect information on diagnosis and management of these tumours. This data will be best assessed by combing these rare cases at a national level recruiting from centres throughout UK and Ireland. The ...

GO TO STUDY Go

Cardiovascular

Evaluation of a Novel Diagnostic Test for Calcium Release Deficiency Syndrome

Millions of people suffer due to cardiac arrest every year and in many cases, the cause of the cardiac arrest is related to a disorder of the electrical activity of the heart. Calcium Release Deficiency Syndrome (CRDS) is a recently discovered electrical heart disorder that develops due to a genetic change in the RyR2 gene resulting in the low activity of RyR2 protein. Currently, CRDS needs genetic testing to be diagnosed and then the identified RyR2 genetic change needs to ...

GO TO STUDY Go

Neurological

Open Network for Frontotemporal dementia Innovation Research (ON-FIRE)

There are many types of dementia. This research studies the family of illnesses known as Frontotemporal type of dementia. This devastating group of illnesses change behaviour, language, and movement. Frontotemporal dementia often affects younger adults and runs in families. There is long running inflammation in the brain with Frontotemporal dementia – suggesting that anti-inflammatory treatments might slow or prevent decline. However, no two people are the same in their symptoms, or in what drives inflammation. For example, genetics, lifestyle, ethnicity ...

GO TO STUDY Go

Metabolic and Endocrine

UK Islet Autoantibody Registry (UKIAb)

We aim to establish a registry of children young people and adults who are IAb positive. We will use the registry to address the following research questions: 1. What is the lived experience of being IAb positive,or having a child who is IAb positive? 2. What are IAb positive individuals’ and their families’ information and support needs? 3. What are the frequency and risk factors associated with clinical outcomes,including progression to Stage 3 T1D in a UK cohort 4. How does the UK IAb positive cohort compare ...

GO TO STUDY Go

Blood

A comparative observational study to evaluate the safety and effectiveness of Xromi® (hydroxycarbamide oral solution 100mg/ml) for the prevention of vaso-occlusive complications of sickle cell disease in children under 2 years of age.

We are conducting a study to gather more information on the safety and effectiveness of Xromi (hydroxyurea), a liquid medicine licensed to treat sickle cell disease (SCD) in children from 9 months of age. We aim to understand its safety profile and efficacy in preventing serious SCD complications (e.g., pain crises, acute chest syndromes, stroke) in children under 2 years when used in standard care. We will compare medical information collected during routine clinical appointments of children under 2 years who ...

GO TO STUDY Go